New Steak 'n Shake product on the way. What to know about the MAHA-approved item
After being lauded by the Trump administration's health movement for its transition away from vegetable oils and using beef tallow to cook its signature shoestring fries, Steak 'n Shake will sell tallow directly to customers.
The Indianapolis-based fast-food chain said its restaurants will start selling grass-fed beef tallow later this month. The chain began cooking its fries in tallow at all of its restaurants earlier this year; but the potatoes are pre-fried in seed oils.
"Buy our 100% Grass-Fed Beef Tallow for your home cooking at any Steak n Shake starting June 23. MAHA!' the chain announced on social media. The posts included an image of a 14-ounce jar.
Steak 'n Shake, a subsidiary of San Antonio, Texas-based Biglari Holdings, has about 400 locations nationwide.
Although the jars will be sold in the restaurants, other Steak 'n Shake-branded products, including chili made by Pinnacle Foods Group and frozen burgers distributed by AdvancePierre Foods, are sold in grocery stores.
Beef tallow is rendered beef fat, sometimes called beef drippings.
Like other solid cooking fats such as butter and coconut oil, beef tallow is made up primarily of saturated fat, including stearic acid, which appears not to raise cholesterol in the same way as other saturated fats, according to Mayo Clinic.
Tallow also contains monounsaturated and polyunsaturated fats, which are considered healthier, as well as fat-soluble vitamins that are vital for various bodily functions, including immune support, bone health, cellular function and skin health.
Steak 'n Shake announced in January that by the end of February, all locations would end the use of vegetable oil and switch to 100% all-natural beef tallow for its fries, onion rings and chicken tenders.
Operations chief Daniels told Fox the company had been considering the move for a while, a directive of owner Sardar Biglari, who as a boy, was impressed with fries he tasted in Belgium that were cooked in beef tallow.
'We wanted to switch years ago but couldn't get a chemical-free, additive-free, all-natural pure beef tallow,' Daniels said. 'He tells me we have to do beef tallow, but we have to do it all-natural and no additives and no preservatives. And we found a supplier who could finally do it for us.'
'We've RFK'd our fries.'
Steak 'n Shake touts beef tallow fries: Early MAHA supporters question chain's process
The move was praised by U.S. health czar Robert F. Kennedy Jr., whose 'Make America Healthy Again' agenda the brand supports.
The U.S. Secretary of Health and Human Services even did a Fox News Channel interview at a Florida Steak 'n Shake, commending the chain.
'Steak and Shake has been great. We're very grateful to them for RFKing the french fries,' Kennedy said. "They turned me into a verb."
Kennedy wants fast food companies to use beef tallow for frying instead of seed oils, like soybean and canola oil, which he has called 'one of the most unhealthy ingredients that we have in foods.'
The chain later said that while it is committed to removing seed oils from its restaurants, its suppliers pre-fry fries, onion rings and chicken tenders in seed oils before freezing them and shipping them to the shops.
Indy Steak 'n Shake $1M renovation: What's new at the downtown restaurant
Republican politicians and high-profile MAGA and MAHA boosters responded positively to Steak 'n Shake's blatant appeal on social media to Kennedy and others tied to the Trump administration. The chain's postings included a red hat with yellow letters saying 'Make Frying Oil Tallow Again,' nodding to the Kennedy-led agenda, and posting images of the health secretary. A version of the hat is available on the Kennedy's MAHA merchandise website.
The chain's social media accounts also made overtures to Tesla and its CEO, Elon Musk, who President Donald Trump tapped to lead an effort to downsize the federal workforce and slash spending.
Contact IndyStar reporter Cheryl V. Jackson at cheryl.jackson@indystar.com or 317-444-6264. Follow her on X.com:@cherylvjackson or Bluesky: @cherylvjackson.bsky.social.
This article originally appeared on Indianapolis Star: Steak 'n Shake's newest product. What to know about the MAHA favorite
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. The complete results from these studies were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025. Simultaneously, results from QWINT-1, a first-of-its-kind fixed-dose study, were published in The New England Journal of Medicine, while results from QWINT-3 and QWINT-4 were published in The Lancet. In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.1,2 In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.3 In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand.4 In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine at week 26 for the efficacy estimand.5 In these two trials, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. "The novel fixed-dose regimen used in QWINT-1 for once-weekly efsitora, which consisted of only four single-dose titration options, has the potential to facilitate and simplify insulin therapy, reducing the hesitation often associated with starting insulin to treat type 2 diabetes," said Dr. Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine, University of Texas Southwestern Medical Center, and lead trial investigator for QWINT-1. "A simpler, once-weekly regimen with efsitora may help people with type 2 diabetes initiate and manage insulin therapy with the goal of improving blood sugar levels. Across all QWINT trials, the results showed that once-weekly efsitora controlled glucose as effectively as the most popular once-daily basal insulins." QWINT-1 Primary EndpointEfficacy Estimand Treatment-RegimenEstimand6 Primary Endpoint – A1C Reduction (Resulting A1C) at Week 52 Efsitora -1.31 % (6.92 %) -1.19 % (7.05 %) Glargine -1.27 % (6.96 %) -1.16 % (7.08 %)QWINT-3 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-RegimenEstimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -0.86 % (6.93 %) -0.81 % (6.99 %) Degludec -0.75 % (7.03 %) -0.72 % (7.08 %) Key Secondary Endpoint – Rates of Clinically Significant or Severe Nocturnal Hypoglycemic Events Per Patient-Year of Exposure up to Week 787,8 Efsitora 0.11 Degludec 0.10 Key Secondary Endpoint – Percent Time in Range (70-180 mg/dL) During the FourWeeks Prior to Week 26 Efsitora 62.8 % 61.4 % Degludec 61.3 % 61.0 %QWINT-4 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-Regimen Estimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -1.07 % (7.12 %) -1.01 % (7.17 %) Glargine -1.07 % (7.11 %) -1.00 % (7.18 %) Key Secondary Endpoint – Participants Achieving A1C <7% at Week 26 Without Nocturnal Hypoglycemia Efsitora 39.5 % 38.6 % Glargine 36.6 % 35.9 % Key Secondary Endpoint – Rates of Clinically Significant or Severe NocturnalHypoglycemic Events Per Patient-Year of Exposure up to Week 26 Efsitora 0.67 Glargine 1.00 "Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," said Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly. "These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach. We look forward to working with regulatory agencies to bring this innovation to patients around the world." Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for the treatment of type 2 diabetes. In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks. In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with efsitora vs. 5.9 with insulin glargine at 26 weeks. Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year. About the QWINT clinical trial programThe QWINT Phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 3,000 people living with type 2 diabetes across four global registration studies. QWINT-1 (NCT05662332) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin using a fixed dose escalation to daily insulin glargine for 52 weeks in insulin-naïve adults with type 2 diabetes. The trial randomized 795 participants across the U.S., Argentina and Mexico to receive efsitora once weekly or insulin glargine once daily, administered subcutaneously. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to daily use of insulin glargine. QWINT-3 (NCT05275400) was a multicenter, randomized, parallel-design, open-label trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 78 weeks after a three-week lead-in followed by a five-week safety follow up period, in adults with type 2 diabetes who are currently treated with basal insulin. The trial randomized 986 participants across the U.S., Argentina, Hungary, Japan, Korea, Poland, Puerto Rico, Slovakia, Spain and Taiwan to receive efsitora once weekly or insulin degludec once daily, administered subcutaneously. The primary objective of the study was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin degludec. QWINT-4 (NCT05462756) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a weekly basal insulin to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized 730 participants across the U.S., Argentina, Germany, India, Italy, Mexico, Puerto Rico and Spain to receive efsitora once weekly or insulin glargine once daily, both of which were administered subcutaneously along with insulin lispro. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin glargine. About insulin efsitora alfaInsulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. P-LLY The efficacy estimand represents the treatment effect on all participants who adhered to the study drug without initiating rescue therapy for persistent severe hyperglycemia. From a baseline of 8.20% for efsitora and 8.28% for insulin glargine. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. From a baseline of 7.80% for both efsitora and insulin degludec. From a baseline of 8.18% for both efsitora and insulin glargine. The treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation or introduction of rescue therapy for persistent severe hyperglycemia. Blood glucose <54 mg/dL. Nocturnal hypoglycemia was defined as any event that occurred at night between midnight and 6 a.m. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about insulin efsitora alfa as a potential treatment for people with type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to insulin efsitora alfa and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that insulin efsitora alfa will prove to be a safe and effective treatment for type 2 diabetes, that insulin efsitora alfa will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Refer to: Niki Biro; niki_biro@ 317-358-9074 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
6 hours ago
- Forbes
Texas Governor Signs Medical Marijuana Program Expansion Bill Into Law
Texas Gov. Greg Abbott has signed a bill to expand the state's limited medical marijuana program, ... More leading activists to declare that Texas has become the 40th state to legalize medical cannabis. Texas Republican Gov. Greg Abbott on Saturday signed legislation to significantly expand the state's medical cannabis program. The new law opens the program to additional patients and products while allowing more licensed operators, leading cannabis policy reform advocacy group the Marijuana Policy Project to declare that Texas has become 'the 40th state to legalize medical cannabis.' 'Following in the footsteps of 39 other states, Texas has embraced a commonsense policy that will ensure that Texans facing serious medical conditions have access to a medicine that's already successfully improving lives nationwide,' Lauren Daly, MPP interim executive director, said in a statement from the group. 'This new law is a direct result of overwhelming public support, acknowledging medical cannabis as a valuable, scientifically supported option for managing chronic pain and debilitating illnesses.' The legislation, House Bill 46 (HB 46), was approved by the Texas House of Representatives on May 13. The state Senate passed an amended version of the bill on May 27, leading to the creation of a conference committee to rectify the differences between the two bills. Both chambers passed the compromise bill on June 2, sending the measure to Abbott for his consideration. The passage of the compromise medical marijuana program expansion bill was welcomed by cannabis policy reform advocates, including members of the Texas Cannabis Policy Center. 'For 10 years, most patients have been excluded from participating in the Compassionate Use Program,' Heather Fazio, executive director of the group, told Marijuana Moment at the time. 'We're happy to see that the legislature is finally expanding the program in a meaningful way.' New Law Expands Texas' Medical Cannabis Program The new law expands the list of conditions that qualify a patient to use medical marijuana, adding chronic pain, traumatic brain injury (TBI), Crohn's disease and other inflammatory bowel diseases. End-of-life patients in palliative or hospice care would also qualify for the Texas Compassionate Use Program (TCUP), as the state's medical cannabis program is known. The measure also expands the types of cannabis products authorized by the TCUP, adding medical marijuana patches and topicals, as well as suppositories, approved inhalers, nebulizers and vaping devices. The legislation also directs the state Department of Public Safety to increase the number of medical cannabis business licenses from three to 15. Licensed providers would also be allowed to operate approved satellite locations. Texas' new medical cannabis law adds new qualifying conditions to the current limited program. Under HB 46, medical cannabis patient registrations will be valid for one year, online cannabis news source Marijuana Moment noted in a report on Saturday. Registered patients will be allowed up to four refills of a 90-day supply of medical cannabis products. Licensed cannabis products will be limited to one gram of total THC per package, with a maximum of 10 milligrams THC allowed per dose. The new law broadens the scope of the TCUP, which was previously limited to patients with one of only eight qualifying medical conditions. The program also limited options for cannabis use, allowing only non-smokable products with less than 0.5% THC. 'For too long, the existing Texas Compassionate Use Program has been severely limited, leaving countless Texans without the relief they desperately need,' said Kevin Caldwell, MPP Southeast legislative manager. 'Texans have spoken, and their voices have been heard. HB 46 will expand access to medical cannabis, a relatively safe and effective treatment option that has long been sought by patients suffering from pain and several other serious medical conditions.' HB 46 requires state regulators to develop rules to implement the legislation by October 1.
New York Times
12 hours ago
- New York Times
‘I Feel Like I've Been Lied To': When a Measles Outbreak Hits Home
He was a chiropractor by training, but in a remote part of West Texas with limited medical care, Kiley Timmons had become a first stop for whatever hurt. Ear infections. Labor pains. Oil workers who arrived with broken ribs and farmers with bulging discs. For more than a decade, Kiley, 48, had seen 20 patients each day at his small clinic located between a church and a gas station in Brownfield, population 8,500. He treated what he could, referred others to physicians and prayed over the rest. It wasn't until early this spring that he started to notice something unfamiliar coming through the door: aches that lingered, fevers that wouldn't break, discolored patches of skin that didn't make sense. At first, he blamed it on a bad flu season, but the symptoms stuck around and then multiplied. By late March, a third of his patients were telling him about relatives who couldn't breathe. And then Kiley started coughing, too. His wife, Carrollyn, had recently tested positive for Covid, but her symptoms eased as Kiley's intensified. He went to a doctor at the beginning of April for a viral panel, but every result came back negative. The doctor decided to test for the remote possibility of measles, since there was a large outbreak spreading through a Mennonite community 40 miles away, but Kiley was vaccinated. 'I feel like I'm dying,' Kiley texted a friend. He couldn't hold down food or water. He had already lost 10 pounds. His chest went numb, and his arms began to tingle. His oxygen was dropping dangerously low when he finally got the results. 'Positive for measles,' he wrote to his sister, in mid-April. 'Just miserable. I can't believe this.' Twenty-five years after measles was officially declared eliminated from the United States, this spring marked a harrowing time of rediscovery. A cluster of cases that began at a Mennonite church in West Texas expanded into one of the largest outbreaks in a generation, spreading through communities with declining vaccination rates as three people died and dozens more were hospitalized from Mexico to North Dakota. Public health officials tracked about 1,200 confirmed cases and countless exposures across more than 30 states. People who were contagious with measles boarded domestic flights, shopped at Walmart, played tuba in a town parade and toured the Mall of America. Want all of The Times? Subscribe.
